MK-8617 is primarily utilized in research settings as a potent and selective inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH). It is extensively studied for its potential therapeutic applications in conditions related to hypoxia, such as anemia, ischemic diseases, and certain types of cancer. By stabilizing HIF proteins, MK-8617 promotes the expression of genes involved in erythropoiesis, angiogenesis, and metabolic adaptation, making it a promising candidate for treating anemia associated with chronic kidney disease. Additionally, its role in enhancing oxygen delivery and cellular survival under low-oxygen conditions has sparked interest in exploring its use for tissue protection and repair in cardiovascular and cerebrovascular diseases. Research is ongoing to further elucidate its efficacy and safety in clinical applications.